Methods

• Multidisciplinary panel convened to develop consensus opinion regarding RWE use of DOACs in obese VTE patients
  • 4 MDs, 2 Pharmacists, 1 Nurse Practitioner, 2 Patient Advocates
• Review of current guidelines and evidence through 2022
• 38 question survey answered by non-patient panelists, followed by videoconference discussion to inform the final opinion

Selected Survey Results

• Real-world practice is not consistent with the updated 2021 ISTH Guidance
• DOACs should be considered in all obese patients, regardless of BMI; however, data is limited in excessive obesity (BMI > 50 kg/m²)
• Peak and trough DOAC levels should not influence management considerations
• Unclear efficacy of reduced dosing in extended VTE prophylaxis

Funding

• By an educational grant from Janssen Pharmaceuticals to MediCom Worldwide, Inc. Janssen had no input into the selection of participants,
  nor the planning, conduct, or analysis of the panel proceedings. Panelists received compensation.